Back to first-pass browser

First-pass extracted concept

MITF DNA binding domain

Candidate: concept label1 source documents5 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

Here, we report on the discovery of ligands for the DNA binding domain of MITF, using fragment-based screening (FBS) by nuclear magnetic resonance (NMR).
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1discoverysupports2025Source 1DOIPubMed

NMR-based fragment screening identified ligands for the MITF DNA binding domain.

Claim 2mechanismsupports2025Source 1DOIPubMed

NMR experiments and molecular dynamics simulations indicate a dynamic conformational exchange between helices in the asymmetric MITF homodimer that is perturbed by ligand binding.

Claim 3noveltysupports2025Source 1DOIPubMed

Direct targeting of MITF or other bHLH-LZ transcription factors was unprecedented before this work.

Claim 4platform scopesupports2025Source 1DOIPubMed

The study advances direct targeting of bHLH-LZ DNA binding domains and provides a basis for further pharmacological inhibition of MITF.

Claim 5therapeutic rationalesupports2025Source 1DOIPubMed

Clinical, genetic, and functional evidence supports MITF as a therapeutically relevant target throughout melanoma disease progression.